These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18363469)

  • 1. Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections.
    Kuti JL; Dowzicky M; Nicolau DP
    Surg Infect (Larchmt); 2008 Feb; 9(1):57-66. PubMed ID: 18363469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
    Kuti JL; Dowzicky M; Nicolau DP
    J Chemother; 2008 Feb; 20(1):69-76. PubMed ID: 18343747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
    Eagye KJ; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2007 Apr; 8(2):215-26. PubMed ID: 17437367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
    Maglio D; Kuti JL; Nicolau DP
    Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline: a critical update.
    Shakil S; Akram M; Khan AU
    J Chemother; 2008 Aug; 20(4):411-9. PubMed ID: 18676218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
    Crandon JL; Kuti JL; Jones RN; Nicolau DP
    Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H; Tan TY; Dowzicky MJ
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL; Fung HB; Mehta D; Riska PF
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
    Housman ST; Sutherland CA; Nicolau DP
    Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.